{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:45:41Z","timestamp":1781289941004,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec><jats:label\/><jats:p>The producers of influenza vaccines are not capable today to meet the global demand for an influenza vaccine in case of pandemic, so the World Health Organization recommends to develop the own influenza vaccine production in each country. A domestic preservative\u2010 and adjuvant\u2010free trivalent split vaccine against seasonal influenza was developed at the Research Institute for Biological Safety Problems. The paper presents the results of assessing safety and immunogenicity of the influenza split vaccine after single immunization of healthy volunteers aged 18\u201050 years in the course of Phase I Clinical Trials. This study was randomized, blind, and placebo\u2010controlled. The volunteers were intramuscularly vaccinated with a dose of split vaccine or placebo. The study has shown that all local and systemic reactions had low degree of manifestation and short\u2010term character, so there was no need in medication. Serious side effects were not observed. On day 21 post vaccination the portion of vaccinated persons with fourfold seroconversions to influenza \u0410\/H1N1pdm09 virus was 100.0%, to influenza \u0410\/H3N2 virus\u201495.5%, to influenza B virus\u201481.8%, and in placebo group this index was 0%. Seroprotection rates against influenza \u0410\/H1N1pdm09, \u0410\/H3N2 and B viruses were 95.5, 86.3, and 72.7%, respectively. Geometric mean titers (GMT) of antibodies by day 21 post vaccination reached 175.7 for influenza \u0410\/H1N1pdm09 virus, 64.2 for influenza \u0410\/H3N2 virus, and 37.6 for influenza B virus; in placebo group GMT growth was not observed. So, the seasonal influenza split vaccine is well tolerated and fits all immunogenicity criteria for human influenza vaccines.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.24922","type":"journal-article","created":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T12:02:40Z","timestamp":1503748960000},"page":"41-49","source":"Crossref","is-referenced-by-count":4,"title":["Safety and immunogenicity of the novel seasonal preservative\u2010 and adjuvant\u2010free influenza vaccine: Blind, randomized, and placebo\u2010controlled trial"],"prefix":"10.1002","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-3936","authenticated-orcid":false,"given":"Gulbanu","family":"Sarsenbayeva","sequence":"first","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Volgin","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markhabat","family":"Kassenov","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"Issagulov","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Bogdanov","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abylay","family":"Sansyzbay","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Abitay","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainur","family":"Nurpeisova","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altynay","family":"Sagymbay","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhumagali","family":"Koshemetov","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stukova","sequence":"additional","affiliation":[{"name":"Influenza Research Institute St.Petersburg Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Buzitskaya","sequence":"additional","affiliation":[{"name":"Influenza Research Institute St.Petersburg Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyas","family":"\u041aulmagambetov","sequence":"additional","affiliation":[{"name":"Centre for Clinical Medicine and Research Almaty Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinara","family":"Karabayeva","sequence":"additional","affiliation":[{"name":"Centre for Clinical Medicine and Research Almaty Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"Davlyatshin","sequence":"additional","affiliation":[{"name":"Clinical Laboratory \u00abT\u2010Helper\u00bb Almaty Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berik","family":"Khairullin","sequence":"additional","affiliation":[{"name":"Research Institute for Biological Safety Problems Gvardeysk Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-6-30"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.065"},{"key":"e_1_2_9_4_1","unstructured":"WHO. Pandemic preparedness and response. WHO Guidance document. 2009. [Last viewed on March 10 2015] Available athttp:\/\/www.who.int\/influenza\/resources\/documents\/pandemic_guidance_04_2009\/en\/."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2008.00054.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28639"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24832"},{"key":"e_1_2_9_8_1","first-page":"1","article-title":"Characterization and circulation of seasonal influenza viruses in Madrid, 2010\u20132016","volume":"9999","author":"Chiarella FC","year":"2017","journal-title":"J Med Virol"},{"key":"e_1_2_9_9_1","unstructured":"WHO. Global pandemic influenza action plan to increase vaccine supply.2006. [Last viewed on March 10 2015] Available athttp:\/\/www.who.int\/csr\/resources\/publications\/influenza\/WHO_CDS_EPR_GIP_2006_1\/en\/."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62026-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1911"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00096-13"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7560.1000205"},{"key":"e_1_2_9_14_1","first-page":"29","article-title":"Comparative study of methods for extraction of highly purified hemagglutinin from H5N1 influenza virus recombinant strain (A\/Astana\/6:2\/2009)","volume":"3","author":"Sarsenbayeva GJ","year":"2013","journal-title":"J App Envir Bio Sci"},{"key":"e_1_2_9_15_1","first-page":"1","article-title":"A novel preservative\u2010free seasonal influenza vaccine safety and immune response studying in the frame of preclinical research","volume":"9999","author":"Sarsenbayeva G","year":"2017","journal-title":"J Med Virol"},{"key":"e_1_2_9_16_1","unstructured":"WHO. Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza.2011. Available athttp:\/\/whqlibdoc.who.int\/publications\/2011\/9789241548090_eng.pdf"},{"key":"e_1_2_9_17_1","unstructured":"WHO. Pandemic influenza vaccines: current status. Pandemic (H1N1) 2009 11. 2009."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.01.034"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.124"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21415"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20801"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0818-9641.2004.01272.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1987.tb04335.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0074-02762012000700014"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00016-12"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0350-4"},{"key":"e_1_2_9_27_1","unstructured":"The Committee for Proprietary Medicinal Products (CHMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP\/BWP\/214\/96. [Last viewed on March 12 1997] Available:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003945.pdf"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1099770"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1009338"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.24922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T13:35:20Z","timestamp":1695735320000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.24922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/jmv.24922"],"URL":"https:\/\/doi.org\/10.1002\/jmv.24922","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]}}}